



PTO/SB/08A (04-07)

Approved for use through 09/30/2007. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 1

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/550,866
		Filing Date	September 23, 2005
		First Named Inventor	Drivas, D.
		Art Unit	1646
		Examiner Name	Mertz, Prema Maria
Sheet	1	of	1
		Attorney Docket Number	MP-02

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear T
		Country Code ³ "Number ⁴ "Kind Code ⁵ (If known)			
PM	WO02093998		11-28-2002	DUOTOL AB	
PM	WO0065058		11-02-2000	M & E BIOTECH A/S	

Examiner
Signature 

Date Considered

914107

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). **²** See *Kinds Codes of USPTO Patent Documents* at www.uspto.gov or MPEP 901.04. **³** Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). **⁴** For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **⁵** Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. **⁶** Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

DEC 9 2005
MP-72
SEARCHED INDEXED
SERIALIZED FILED
US PATENT & TRADEMARK OFFICE

Sheet 1 of 1

Complete if Known	
Application Number	10/550,866
Filing Date	September 23, 2005
First Named Inventor	Dimitrios T. Drivas
Group Art Unit	
Examiner Name	
Attorney Docket No: MP-02	

US PATENT DOCUMENTS

Examiner Initials*	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
PM	2005/0013799A1	1/2005	Skurkovich et al.	
	2005/0013800A1	1/2005	Skurkovich et al.	
	2003/0175290A1	9/2003	Renner et al.	
	6,403,782 B1	6/2002	Luster et al.	
	2002/0098523A1	7/2002	Vaughan et al.	
	6,093,405	7/2000	Zagury et al.	
	5,993,814	11/1999	Williams et al.	
	60/396,636		Bachmann et al.	
↓	60/331,045		Renner et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
PM	WO 04/096849 A2	11-11-2004	University of Manitoba and Manitoba Institute of Child Health		
	WO 03/082349 A1	10-09-2003	Mercia Pharma, LLC		
	WO 03/040164 A2	05-15-2003	Cytos Biotechnology AG		
	WO 02/056905 A2	07-25-2002	Cytos Biotechnology AG		
	WO 01/66754 A1	09-13-2001	Cambridge Antibody Technology Limited		
	WO 99/10534	03-04-1999	Center for Blood Research, Inc.		
↓	WO 95/07985	03-23-1995	National Heart & Lung Institute; Ludwig Institute for Cancer Research		

EXAMINER *Renu Menk*DATE CONSIDERED *9/4/07*

<p>Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i></p>		<i>Complete if Known</i>	
		Application Number	10/550,866
		Filing Date	September 23, 2005
		First Named Inventor	Dimitrios T. Drivas
		Group Art Unit	
		Examiner Name	
Sheet 2 of 2		Attorney Docket No: MP-02	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
P M		JOSE, P.J., et al. <i>Eotaxin: Cloning of an Eosinophil Chemoattractant Cytokine and Increased mRNA Expression in Allergen-Challenged Guinea-Pig Lungs, Biochemical and Biophysical Research Communications</i> , November 1994, pages 788-794, Vol. 205, No. 1.	
		JOSE, P.J., et al. <i>Eotaxin: A Potent Eosinophil Chemoattractant Cytokine Detected in a Guinea Pig Model of Allergic Airways Inflammation</i> , J. Exp. Med., March 1994, pages 881-887, Vol. 179.	
		GARCIA-ZEPEDA, E., et al. <i>Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia, Nature Medicine</i> , April 1996, pages 449-456, Vol. 2, No. 4.	
		HERTZ, M., et al. <i>Active Vaccination Against IL-5 Bypasses Immunological Tolerance and Ameliorates Experimental Asthma, Journal of Immunology</i> , October 2001, pages 3792-3799, Vol. 167, No. 7.	
		GUTIERREZ-RAMOS, J.C., et al. <i>Eotaxin: From an Eosinophilic Chemokine to a Major Regulator of Allergic Reactions, Immunology Today</i> , November 1999, pages 500-504, Vol. 20, No. 11.	
		PONATH, P.D., et al. <i>Cloning of the Human Eosinophil Chemoattractant, Eotaxin Expression, Receptor Binding, and Functional Suggest a Mechanism for the Selective Recruitment of Eosinophils, Journal of Clinical Investigation</i> , February 1996, pages 604-612, Vol. 97, No. 3.	
↓		TANNENBAUM, C.S., et al. <i>The CXC Chemokines IP-10 and Mig are Necessary for IL-12-Mediated Regression of the Mouse RENCA Tumor, Journal of Immunology</i> , July 1998, pages 927-932, Vol. 161, No. 2.	

EXAMINER *Prerna Mehta*

DATE CONSIDERED

9/4/07

10/50866

PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0551-0031
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known	
Application Number	TBD JC09 Rec'd PCT/PTO 23 SEP 2005,
Filing Date	
First Named Inventor	Dimitrios T. Drivas
Group Art Unit	
Examiner Name	
Sheet 1 of 2 Attorney Docket No: MP-02	

US PATENT DOCUMENTS

Examiner Initials*	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
PM	2005/0013799A1	1/2005	Skurkovich et al.	
	2005/0013800A1	1/2005	Skurkovich et al.	
	2003/0175290A1	9/2003	Renner et al.	
	2002/0098523A1	7/2002	Vaughan et al.	
	6,403,782 B1	6/2002	Luster et al.	
	6,093,405	7/2000	Zagury et al.	
	5,993,814	11/1999	Williams et al.	
	60/396,636		Bachmann et al.	
	60/331,045		Renner et al.	
↓				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
PM	WO 04/096849 A2	11-11-2004	University of Manitoba and Manitoba Institute of Child Health		
	WO 03/082349 A1	03-24-2003	Mercia Pharma, LLC		
	WO 03/040164 A2	05-15-2003	Cytos Biotechnology AG		
	WO 02/056905 A2	07-25-2002	Cytos Biotechnology AG		
↓	WO 01/66754 A1	09-13-2001	Cambridge Antibody Technology Limited		

EXAMINER

Prima Menz

DATE CONSIDERED

9/4/07

Substitute Disclosure Statement Form (PTO-1449)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

10/550866

PTO/BBO1A(08-03)

Approved for use through 07/31/2008, OMB 0651-0031
U.S. Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known	
Application Number	TBD 3C09 Rec'd PCT/PTO 23 SEP 2005
Filing Date	
First Named Inventor	Dimitrios T. Drivas
Group Art Unit	
Examiner Name	
Sheet 2 of 2	Attorney Docket No: MP-02

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PM		JOSE, P.J., et al. <i>Eotaxin: Cloning of an Eosinophil Chemoattractant Cytokine and Increased mRNA Expression in Allergen-Challenged Guinea-Pig Lungs</i> , Biochemical and Biophysical Research Communications, November 1994, pages 788-794, Vol. 205, No. 1.	
		JOSE, P.J., et al. <i>Eotaxin: A Potent Eosinophil Chemoattractant Cytokine Detected in a Guinea Pig Model of Allergic Airways Inflammation</i> , J. Exp. Med., March 1994, pages 881-887, Vol. 179	
↓		GARCIA-ZEPEDA, E., et al. <i>Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia</i> , Nature Medicine, April 1996, pages 449-456, Vol. 2, No. 4.	

EXAMINER

Penna Menty

DATE CONSIDERED

9/4/07

Substitute Disclosure Statement Form (PTO-1449)

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached